| Ticker | RCUS |
|---|---|
| ISIN | US03969F1093 |
| Sector | Atención sanitaria |
| Mercado | NYSE |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-lin...
El precio actual de Arcus Biosciences, Inc. (RCUS) es de 25,50 , con una variación del 1,47%.
Arcus Biosciences, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones